ALK and non-small cell lung carcinoma: Entrectinib—a CNS-active multikinase inhibitor targeting ROS1, TRK A/B/C, and ALK—received U.S. Food and Drug Administration (FDA) approval in 2019 as first-line therapy for ROS1-positive metastatic NSCLC (7).